{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:18:09Z","timestamp":1790396289119,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,25]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.<\/jats:p>","DOI":"10.1182\/blood-2016-05-717355","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T23:23:57Z","timestamp":1468538637000},"page":"1112-1120","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":209,"title":["Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy"],"prefix":"10.1182","volume":"128","author":[{"given":"Vindi","family":"Jurinovic","sequence":"first","affiliation":[{"name":"Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;"},{"name":"Institute for Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Staiger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;"},{"name":"Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tu\u0308bingen, Tu\u0308bingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szczepanowski","sequence":"additional","affiliation":[{"name":"Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;"},{"name":"Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tu\u0308bingen, Tu\u0308bingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Wu\u0308rzburg, and Comprehensive Cancer Center Mainfranken, Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;"},{"name":"German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;"},{"name":"German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2019111905534221800_B1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma.","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2019111905534221800_B2","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma.","volume":"122","author":"Kridel","year":"2012","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111905534221800_B3","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3109\/10428194.2014.885513","article-title":"Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.","volume":"55","author":"Mozessohn","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2019111905534221800_B4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study.","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111905534221800_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1664.1664","article-title":"Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era [abstract].","volume":"124","author":"Maurer","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111905534221800_B6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2019111905534221800_B7","article-title":"Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts) [abstract].","volume":"33","author":"Sargent","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111905534221800_B8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111905534221800_B9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111905534221800_B10","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111905534221800_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9759","key":"2019111905534221800_B12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"2019111905534221800_B13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"issue":"24","key":"2019111905534221800_B14","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2019111905534221800_B15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","article-title":"MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.","volume":"971","author":"Pott","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2019111905534221800_B16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.","volume":"28","author":"Ladetto","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2019111905534221800_B17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111905534221800_B18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence.","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"issue":"27","key":"2019111905534221800_B19","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2019111905534221800_B20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2019111905534221800_B21","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111905534221800_B22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7427","key":"2019111905534221800_B23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"1","key":"2019111905534221800_B24","first-page":"1","article-title":"Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.","volume":"2","author":"Andersen","year":"2012","journal-title":"Leuk Res Rep"},{"issue":"18","key":"2019111905534221800_B25","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111905534221800_B26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.immuni.2015.10.021","article-title":"PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones.","volume":"43","author":"Sander","year":"2015","journal-title":"Immunity"},{"issue":"8","key":"2019111905534221800_B27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/8\/1112\/1465676\/1112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/8\/1112\/1465676\/1112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:53:55Z","timestamp":1574142835000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/8\/1112\/35744\/Clinicogenetic-risk-models-predict-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-717355","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}